Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Praveen Tyle
AddedMar 31, 2024
UpdatedMay 31, 2026
Praveen Tyle

Praveen Tyle

Board Member, Kiora Pharmaceuticals

Crunchbase

Praveen Tyle's Career

Kiora Pharmaceuticals
Kiora Pharmaceuticals

Encinitas, CA, US

Board Member· Board
Skye Bioscience
Skye Bioscience

Costa Mesa, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Praveen Tyle's Career

Kiora Pharmaceuticals
Kiora Pharmaceuticals
Public$106.5M142004Encinitas, CA, US
Board Member· Board

Leadership at Kiora Pharmaceuticals

Paul ChaneyPaul ChaneyBoard Member
Ken GayronKen GayronBoard Member
Brian StremBrian StremBoard Member
Bernd MuehlenwegBernd MuehlenwegCo-Founder

Similar to Kiora Pharmaceuticals

Alimera SciencesAlimera SciencesAlpharetta, GA, USPharmaceuticalsest. 2003Alimera SciencesAlpharetta, GA, US · est. 2003

Alimera Sciences Inc.: A biopharmaceutical company specializing in ophthalmic pharmaceuticals.

Public · $304.4M145
EyePointEyePointWatertown, MA, USDrug Devicesest. 2008EyePointWatertown, MA, US · est. 2008

EyePoint Pharmaceuticals, a global biopharmaceutical firm, develops drug devices for chronic eye disorders.

Public · $653.8M144
EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
Ocular TherapeutixOcular TherapeutixBedford, MA, USOphthalmic Therapiesest. 2006Ocular TherapeutixBedford, MA, US · est. 2006

Ocular Therapeutix, Inc.: Global biopharma innovator in hydrogel-based ophthalmic therapies.

Public · $386.5M274
Skye Bioscience
Skye Bioscience
Public$725k92012Costa Mesa, CA, US
Board Member· Board

Leadership at Skye Bioscience

Punit DhillonPunit DhillonBoard Member
Jim HeppellJim HeppellBoard Member

Similar to Skye Bioscience

Diverse BiotechDiverse BiotechOrlando, FL, USCannabinoid Drugsest. 2013Diverse BiotechOrlando, FL, US · est. 2013

Leaf Vertical: A clinical-stage biopharmaceutical firm innovating therapeutic cannabinoid drugs.

Public · $1M30
Biopharmaceutical ResearchBiopharmaceutical ResearchCastroville, CA, USPharmaceuticals, THC Testingest. 2017Biopharmaceutical ResearchCastroville, CA, US · est. 2017

Pharmaceutical manufacturer and researcher specializing in cannabis-based plant therapeutics and USDA-compliant THC testing.

Series A · $20M22
Applied BiosciencesApplied BiosciencesBeverly Hills, CA, USCBD Products, Therapeuticsest. 2014Applied BiosciencesBeverly Hills, CA, US · est. 2014

Applied Biosciences Corp. develops and commercializes cannabinoid therapeutics and THC-free CBD products in the US.

Public · $1M11
Emerald Health PharmaceuticalsEmerald Health PharmaceuticalsSan Diego, CA, USMedicine, Pharmaceuticalsest. 2017Emerald Health PharmaceuticalsSan Diego, CA, US · est. 2017

Emerald Heath Pharmaceuticals: Innovating cannabinoid-based medicines for incurable diseases.

Public · $300k17

Praveen Tyle's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Praveen Tyle

Peter SvennilsonPeter SvennilsonFounder · The Column GroupScott MorrisonScott MorrisonBoard Member · Zai LabSylvie GrégoireSylvie GrégoireBoard Member · Vifor PharmaHoward B. RosenHoward B. RosenBoard Member · TalpheraJames FoghtJames FoghtBoard Member · Oncolyze